Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study

INTRODUCTION: METEOR was a phase 3 trial (NCT01865747) of cabozantinib versus everolimus in adults with advanced or metastatic clear cell RCC previously treated with VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs). This post hoc analysis of METEOR compared outcomes for patients recruited fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidinger, Manuela, Motzer, Robert J., Rolland, Frederic, Staehler, Michael, Rink, Michael, Retz, Margitta, Csoszi, Tibor, McCaffrey, John A., De Giorgi, Ugo, Caserta, Claudia, Duran, Ignacio, Benzaghou, Fawzi, Clary, Douglas O., Albiges, Laurence, Choueiri, Toni K., Tannir, Nizar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357268/
https://www.ncbi.nlm.nih.gov/pubmed/34736367
http://dx.doi.org/10.1080/0284186X.2021.1995041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357268/
https://www.ncbi.nlm.nih.gov/pubmed/34736367
http://dx.doi.org/10.1080/0284186X.2021.1995041

Ejemplares similares